KalVista Pharmaceuticals (KALV) Current Assets (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Current Assets data on file, last reported at $205.9 million in Q3 2025.

• For the quarter ending Q3 2025, Current Assets rose 7.44% year-over-year to $205.9 million; the trailing twelve-month figure through Jul 2025 stood at $205.9 million (up 7.44% YoY), and the FY2025 full-year result was $241.7 million, up 7.09% from the prior year.
• Current Assets slipped to $205.9 million in Q3 2025, from $241.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $286.0 million in Q4 2024 to a low of $62.5 million in Q1 2021.
• A 5-year average of $189.0 million and a median of $192.1 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 243.12% in 2022 and slumped 45.82% in 2024, its largest moves.
• Tracing KALV's Current Assets over 5 years: stood at $234.5 million in 2021, then sank by 35.51% to $151.2 million in 2022, then dropped by 14.95% to $128.6 million in 2023, then soared by 122.37% to $286.0 million in 2024, then fell by 28.0% to $205.9 million in 2025.
• Business Quant data shows KALV's Current Assets at $205.9 million in Q3 2025, $241.7 million in Q2 2025, and $286.0 million in Q4 2024.